<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management implications of a pathogenic or likely pathogenic variant in a Lynch syndrome gene*</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management implications of a pathogenic or likely pathogenic variant in a Lynch syndrome gene*</h1>
<div class="graphic"><div class="figure"><div class="ttl">Management implications of a pathogenic or likely pathogenic variant in a Lynch syndrome gene*</div><div class="cntnt"><table cellspacing="0"><colgroup width="30%"></colgroup><colgroup width="70%"></colgroup> <tbody> <tr> <td class="subtitle1">Patient population</td> <td class="subtitle1">Intervention(s) that may be appropriate</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Risk reduction</td> </tr> <tr> <td class="indent1">All individuals</td> <td> <ul> <li>Increased CRC surveillance (early initiation and increased frequency of colonoscopy)</li> <li>Possible aspirin chemoprevention after discussion of risks and uncertain benefit</li> <li>Surveillance upper endoscopy with visualization of the duodenum</li> <li><em>Helicobacter pylori</em> testing and treatment if positive</li> <li>Possible screening urinalysis</li> <li>Possible annual skin examination</li> <li>Preconception counseling; some may opt for alternative reproductive technologies (donor gametes, IVF with PGT)</li> </ul> </td> </tr> <tr> <td class="indent1">Females (in addition to surveillance and interventions for all individuals above)</td> <td> <ul> <li>Education regarding symptoms of endometrial and ovarian cancer</li> <li>Discussion of hysterectomy and rrBSO, typically done after childbearing is complete and/or at the time of CRC resection</li> <li>Discussion of transvaginal ultrasound, endometrial biopsy, and CA-125 testing for those who have not undergone hysterectomy and rrBSO</li> <li>Hormonal chemoprevention for those who are premenopausal and have not undergone hysterectomy and rrBSO</li> </ul> </td> </tr> <tr> <td class="indent1">Males (in addition to surveillance and interventions for all individuals above)</td> <td> <ul> <li>In <em>MSH2</em> and <em>MSH6</em> carriers, discussion of prostate cancer screening by prostate-specific antigen test at age 40 and follow-up in a high-risk cancer screening clinic</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="2">Family members</td> </tr> <tr> <td class="indent1">First- and second-degree relatives</td> <td> <ul> <li>Genetic counseling and consideration of testing for adult at-risk relatives</li> <li>Cascade testing of their relatives if appropriate</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="2">Cancer management</td> </tr> <tr> <td class="indent1">Colorectal</td> <td> <ul> <li>More extensive surgery</li> <li>Possible use of cancer immunotherapy (eg, PD-1 inhibitor) as second-line option</li> </ul> </td> </tr> <tr> <td class="indent1">Endometrial cancer</td> <td> <ul> <li>Management as for the general population</li> <li>Possible use of cancer immunotherapy (eg, PD-1 inhibitor) as second-line option</li> </ul> </td> </tr> <tr> <td class="indent1">Other cancers</td> <td> <ul> <li>Management as for the general population</li> <li>Possible use of cancer immunotherapy (eg, PD-1 inhibitor) as second-line option</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">This table is intended as an information summary and should not take the place of the clinical judgment of the treating specialists. Refer to UpToDate topics on hereditary colorectal cancer syndromes for important information.</div><div class="graphic_footnotes"><p>CRC: colorectal cancer; IVF: in vitro fertilization; PGT: preimplantation genetic testing; rrBSO: risk-reducing bilateral salpingo-oophorectomy; PD-1: programmed death 1; MMR: mismatch repair.</p>
* Refers to a germline variant; includes variants in MMR genes <em>MLH1</em>, <em>MSH2</em>, <em>MSH6</em>, <em>PMS2</em>, and the <em>EPCAM</em> gene. Pathogenic or likely pathogenic variants in other MMR genes are very rare and management is individualized.</div><div id="graphicVersion">Graphic 122460 Version 7.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
